DRR168522
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V1+0.240
- SPERMATOGENESIS+0.200
- MYC_TARGETS_V2+0.130
- UNFOLDED_PROTEIN_RESPONSE+0.130
- ANDROGEN_RESPONSE+0.090
- GLYCOLYSIS+0.080
- ESTROGEN_RESPONSE_LATE+0.070
- OXIDATIVE_PHOSPHORYLATION+0.070
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.510
- HEDGEHOG_SIGNALING-0.490
- TGF_BETA_SIGNALING-0.490
- INTERFERON_GAMMA_RESPONSE-0.420
- IL6_JAK_STAT3_SIGNALING-0.410
- COMPLEMENT-0.400
- INFLAMMATORY_RESPONSE-0.390
- TNFA_SIGNALING_VIA_NFKB-0.380
- APOPTOSIS-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.888 |
| 2 | TCGA-NC-A5HI-01A-11R-A26W-07 | — | cohortSQ1 | 0.886 |
| 3 | TCGA-CR-6472-01A-11R-1873-07 | — | — | 0.883 |
| 4 | SRR8518240 | — | E | 0.882 |
| 5 | TCGA-77-A5G7-01B-11R-A27Q-07 | — | cohortSQ1 | 0.878 |
| 6 | BS_9NJHQE9F | medulloblastoma | — | 0.871 |
| 7 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.871 |
| 8 | TCGA-63-A5MI-01A-12R-A27Q-07 | — | cohortSQ1 | 0.870 |
| 9 | SRR8518239 | — | E | 0.870 |
| 10 | SRR8943037 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.040 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |